Florian von Raison
Overview
Explore the profile of Florian von Raison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kapoor R, Smith K, Allegretta M, Arnold D, Carroll W, Comabella M, et al.
Neurology
. 2020 Jul;
95(10):436-444.
PMID: 32675076
There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome...
2.
Hagerman R, Jacquemont S, Berry-Kravis E, Portes V, Stanfield A, Koumaras B, et al.
Sci Rep
. 2018 Nov;
8(1):16970.
PMID: 30451888
Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral...
3.
Berry-Kravis E, Lindemann L, Jonch A, Apostol G, Bear M, Carpenter R, et al.
Nat Rev Drug Discov
. 2017 Dec;
17(4):280-299.
PMID: 29217836
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of...
4.
Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, et al.
Mov Disord
. 2016 May;
31(7):1054-8.
PMID: 27214258
Background: Two phase 2 randomized, double-blind studies were designed to evaluate efficacy and safety of immediate-release (study 1) and modified-release (study 2) mavoglurant formulations in PD l-dopa-induced dyskinesia. Methods: Patients...
5.
Bailey Jr D, Berry-Kravis E, Wheeler A, Raspa M, Merrien F, Ricart J, et al.
J Neurodev Disord
. 2016 Feb;
8:1.
PMID: 26855682
Background: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in...
6.
Berry-Kravis E, Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, et al.
Sci Transl Med
. 2016 Jan;
8(321):321ra5.
PMID: 26764156
Fragile X syndrome (FXS), the most common cause of inherited intellectual disability and autistic spectrum disorder, is typically caused by transcriptional silencing of the X-linked FMR1 gene. Work in animal...
7.
Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, et al.
Expert Opin Investig Drugs
. 2013 Nov;
23(1):125-34.
PMID: 24251408
Introduction: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. With no curative treatment available, current therapeutic approaches are aimed at symptom management. FXS is caused...
8.
Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, et al.
Psychopharmacology (Berl)
. 2013 Nov;
231(6):1237-50.
PMID: 24173622
Rationale: Advances in understanding the underlying mechanisms of conditions such as fragile X syndrome (FXS) and autism spectrum disorders have revealed heterogeneous populations. Recent trials of novel FXS therapies have...
9.
Lefaucheur J, Gurruchaga J, Pollin B, von Raison F, Mohsen N, Shin M, et al.
Eur Neurol
. 2008 Aug;
60(4):186-99.
PMID: 18667827
Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) gained general acceptance in the treatment of Parkinson's disease (PD). Objective: To study the clinical outcome and the predicting factors...
10.
Lefaucheur J, Drouot X, von Raison F, Menard-Lefaucheur I, Cesaro P, Nguyen J
Clin Neurophysiol
. 2004 Oct;
115(11):2530-41.
PMID: 15465443
Objective: To assess the effects of focal motor cortex stimulation on motor performance and cortical excitability in patients with Parkinson's disease (PD). Methods: Repetitive transcranial magnetic stimulation (rTMS) was performed...